APHCON CTN CHAIR: DR DAVID RITCHIE

Picture
Dr Ritchie is Professor of Medicine; Head of Bone Marrow Transplant Service
Dept of Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia.

Dr Ritchie is President of the Hematology Society of Australia and NewZealand and has served as the Chair, BMT group for Australasian Leukaemia and Lymphoma Group (ALLG). Dr Ritchie has trained fellows in allogeneic and autologous stem cell transplant as well as in translational research. 


APHCON Commitment: Developing the clinical trial network program with the vision of increasing participation of the APHCON member institutions. Help in developing investigator initiated studies and implementation of industry sponsored trials.

Clinical Trial Network

APHCON CTN provides the opportunity for both investigator initiated studies as well as industry sponsored studies to be conducted in a seamless fashion.  Our goal is to strengthen the communication and develop symbiotic relationship between the sponsor and investigator in order to build a true network with strong working relationships.

Objectives:
1.Organized Research: The members of APHCON undergo rigorous accreditation process to become members of the APHCON CTN.   
2. Direct Access. APHCON CTN provides open lines of communications between the sponsor and the investigators. This leads to improved research and better collaborations. Such interaction lays the foundation for consistent and reliable outcomes. Please click here for APHCON Principal Investigators and particicpating centers.

Investigator Initiated Studies
APHCOPN CTN provides a solution oriented approach for the member investigators who have novel ideas and strategy to conduct phase I/II studies. The investigator initiates the LOI and APHCON CTN is able to connect the investigator to the appropriate sponsor.

Industry Sponsored Studies
APHCON CTN provides a conduit for direct access to the qualifying member investigators as well as APHCON accredited institutions. The goal is to provide access for the investigators to be able to participate in funded studies and help patients by providing novel therapeutics. In return, the industry partners are able to partner up with credible and well respected investigators leading to improved execution of the clinical trial with dependable results.